Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRR14L_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRR14L_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRR14L_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRR14L_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PRR14L | SNV | Missense_Mutation | rs781464777 | c.1279C>T | p.Arg427Cys | p.R427C | Q5THK1 | protein_coding | tolerated(0.12) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524T>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PRR14L | SNV | Missense_Mutation | | c.2005N>A | p.Asp669Asn | p.D669N | Q5THK1 | protein_coding | tolerated(0.12) | benign(0.011) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PRR14L | SNV | Missense_Mutation | rs775406287 | c.5524N>C | p.Ser1842Pro | p.S1842P | Q5THK1 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PRR14L | SNV | Missense_Mutation | | c.1099G>A | p.Gly367Ser | p.G367S | Q5THK1 | protein_coding | tolerated(0.33) | benign(0.009) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |